Skip to content

Effect of efficacy and safety study of remimazolam in ultrasound-guided nerve block: a randomized controlled trial.

Effect of efficacy and safety study of remimazolam in ultrasound-guided nerve block: a randomized controlled trial.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035388
Enrollment
Unknown
Registered
2020-08-09
Start date
2020-08-14
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthetic

Interventions

Ramazolam group (R group):Remimazolam
Dexmedetomidine group (D group):Dexmedetomidine

Sponsors

Department of Anesthesiology, Anhui Provincial Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are scheduled for ultrasound-guided nerve block before anesthesia; 2. Patients with ASA grade I ~ III; 3. Patients aged 18-75 years old; 4. Patients without obvious dyspnea and hypoxemia before operation; 5. Patients with educational level above primary school; 6. Patients with preoperative MMSE score >= 23; 7. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiovascular disease ,peripheral neuropathy, central nervous system disease, puncture site infection,coagulation disorder; (2) patients with mental disorders; (3) BMI>=35kg/m2 (4) pregnant women; (5) lactating women; (6) failure to follow up, drop out of the study due to personal factors, and (7) patients who are allergic to drugs in this study; (8) history of taking benzodiazepines and other sedative drugs; (9) patients with communication disorders.

Design outcomes

Primary

MeasureTime frame
Hemodynamic index;Spo2;modified observer's assessment of alert /sedation;Depth of anesthesia, Nacrotrend;

Secondary

MeasureTime frame
Incidence of hypoxemia;Incidence of injection pain;

Countries

China

Contacts

Public ContactXiao Yimin

Anhui Provincial Cancer Hospital

869813989@qq.com+86 17756974670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026